Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +50

Moderna Soars 8% on Early Multiple Myeloma Data for Its Three-in-One mRNA Therapy

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ Moderna stock jumped 8% after mRNA-2808 showed four confirmed responses in 11 heavily pretreated multiple myeloma patients.

πŸ’‰ The therapy successfully directs the body to produce three T-cell engagers simultaneously, a key validation of the company's platform technology.

⚠️ While cytokine release syndrome was mild, 41.7% of patients experienced Grade 3 or worse treatment-related side effects during the trial.

πŸ“‰ Moderna's stock trades at 46x forward sales, well above its five-year average of 7.9x, reflecting high expectations for its pipeline.

πŸ₯ The company faces years of development before mRNA-2808 can challenge approved bispecific drugs from Johnson & Johnson and Pfizer.

πŸ“… Moderna is scheduled to report third-quarter financial results on Friday, which may show further declines in Comirnaty revenue.

πŸ—“οΈ Updated clinical data for the multiple myeloma therapy will be presented at the American Society of Hematology meeting on December 12.

Bullish Signals
  • Moderna shares surged 8% following early clinical data showing mRNA-2808 achieved four confirmed responses among 11 heavily pretreated multiple myeloma patients.
  • The trial successfully demonstrated that the company's platform can get the body to produce three T-cell engagers simultaneously, with all three targets detected in patient blood.
  • mRNA-2808 showed no dose-limiting toxicities, distinguishing it from approved competitors that require step-up dosing to manage cytokine release syndrome.
Risk Factors
  • The trial observed Grade 3 or worse treatment-related side effects in 41.7% of patients, indicating significant safety challenges for the novel therapy.
  • mRNA-2808 is still in Phase 1/2 development and faces years of work before it can challenge established competitors like Johnson & Johnson and Pfizer.
  • Moderna's stock trades at a premium valuation of 46x forward sales, significantly higher than its five-year average of 7.9x, leaving little room for error in future trials.
Full Analysis
Moderna (MRNA) shares surged 8% following early clinical data for its experimental multiple myeloma therapy, mRNA-2808. The Phase 1/2 trial demonstrated the platform's ability to instruct cells to produce three T-cell engagers simultaneously, achieving four confirmed responses among 11 heavily pretreated patients. Notably, all three targeted proteins were detected in patient blood samples, validating the technology's delivery mechanism. Despite the positive platform validation, the therapy faces a long path to commercialization, with years remaining before it could challenge established competitors like Johnson & Johnson, Pfizer, and Regeneron. The trial observed mild cytokine release syndrome but noted that 41.7% of patients experienced Grade 3 or worse treatment-related side effects, highlighting safety challenges inherent to this novel approach. Moderna's stock valuation remains elevated at approximately 46x forward sales, significantly above its five-year average of 7.9x. While the company is preparing to report third-quarter results on Friday, which may reveal further declines in Comirnaty revenue due to narrower U.S. vaccine recommendations, today's data reinforces the long-term potential of its mRNA platform despite current financial headwinds. The company plans to present updated data at the American Society of Hematology meeting on December 12. Analysts are closely watching whether this early success translates into broader efficacy in larger trials, given that the current sample size is small and the therapy targets a population with limited prior treatment options.